Beam Therapeutics is trading at $27.75, up 5.39%, with biotech-sector strength the clearest context.
- XBI rose 2.13% during the regular session.
- Beam reported a Q3 loss and sharply lower revenue.
- The company reiterated that a risto-cel BLA filing could come as early as year-end 2026 and projected cash runway into mid-2029. Available evidence does not establish that earnings directly caused the gain.